R

Roche

Global pharmaceuticals and diagnostics company

Java Developer

Full-TimePosted on 10/21/2026Deadline 10/23/26
No salary listed
Mid, Senior
Pune, Maharashtra, India
In Person
Software EngineeringBackend Engineering

About the job

Requirements
  • At least 4 years of professional JVM development, with recent work on Java 17 or Java 21 and Spring Boot.
  • Strong understanding of OAuth 2.0, OpenID Connect, JSON Web Tokens, and Security Assertion Markup Language, including authorization code with PKCE, token exchange, and refresh-token rotation.
  • Hands-on relational database experience, including schema design, indexing, query tuning, and versioned migrations with Liquibase or Flyway.
  • Practical AWS experience running production workloads involving messaging, storage, secrets, and IAM.
  • Experience with Docker and container-based local development, including Docker Compose and Testcontainers.
  • Strong automated testing discipline.
  • Experience with Git-based trunk or feature-branch workflows, CI/CD pipelines, and code review.
  • Clear written communication in English and ability to document decisions and trade-offs.
Responsibilities
  • Design and ship backend services in Java 21 and Spring Boot using REST through Spring MVC, Jersey/JAX-RS, and Spring Cloud Gateway on WebFlux.
  • Extend Keycloak 26 through custom SPIs, authentication flows, and themes, and contribute to realm configuration managed as code.
  • Build event-driven and data-backed features on AWS using SQS/SNS, S3, and Secrets Manager, with PostgreSQL and Liquibase schema migrations.
  • Drive the strangler-pattern migration of legacy identity services with zero-downtime cutovers.
  • Design API contracts first using OpenAPI/springdoc, generated clients, and contract diffing in CI, and keep them backward compatible.
  • Write tests at every level using JUnit 5, AssertJ, Mockito, ArchUnit, Testcontainers with Postgres and LocalStack, WireMock, and REST Assured.
  • Own services in production using Datadog APM/RUM, Micrometer/OpenTelemetry, structured JSON logging, and on-call participation.
  • Ship through GitHub Actions pipelines with SonarQube quality gates, JaCoCo coverage, CycloneDX SBOMs, and strict Gradle dependency locking.
  • Review peers' code and participate in architecture decisions.
Desired Qualifications
  • Direct Keycloak experience with custom providers, SPIs, admin client, or theming, or comparable identity-provider work with Auth0, Gigya, Okta, or ForgeRock.
  • Gradle Kotlin DSL experience in a multi-module or platform-BOM setup.
  • React 18 and TypeScript with Vite, sufficient to own a full vertical slice through the user interface.
  • Node.js/Express services in TypeScript.
  • Kubernetes and Helm, and Terraform for infrastructure and identity-provider configuration as code.
  • Observability practice involving dashboards, SLOs, alerting, and debugging distributed traces.
  • Experience in a regulated environment such as healthcare or life sciences, including GxP, HIPAA, or GDPR, with data privacy as a first-class concern.
  • Python for tooling or automation, Ruff, or pytest.
  • Playwright or Cypress end-to-end testing, or visual regression testing.
  • Performance or load testing with k6 or JMeter.
  • Application security background involving OWASP Top 10, SAST/DAST, dependency hygiene, or SBOM hygiene.

About the company

R

Roche

View
Website

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 16th, 2026
FDA approves Roche's Enspryng as first at-home injection for thyroid eye disease

Roche said the US Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and a patient or caregiver can administer it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis (eye bulging) response, against 23.4% on placebo. Double vision fell in 60.7% of patients, against 25.8%. The SatraGO-1 trial missed its primary endpoint at Week 24. No new safety signals emerged. TED affects about 155 in every 100,000 people in the US. This is Enspryng's second approval, after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for myelin oligodendrocyte glycoprotein antibody-associated disease, with a decision expected in January 2027.

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.

PR Newswire
Sep 30th, 2026
Roche launches newborn screening test for SMA, SCID and sickle cell disease

Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.